Drug Profile
Research programme: eye disorder and wound therapeutics - NuvOx Pharma
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Class Eye disorder therapies; Oxygen compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders; Wounds
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Eye disorders in USA (unspecified route) (NuvOx Pharma website; Spetember 2023)
- 04 Sep 2023 Discontinued for Wounds in USA (unspecified route) (NuvOx Pharma website; Spetember 2023)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Eye-disorders in USA